Understanding how melanoma cells change and resist treatment
Official title: Transcriptional Reprogramming in Melanoma Plasticity
Funded at Wistar Institute · NIH-10858175 · Data updated 2026-11-12
This study is looking at how advanced melanoma, a serious skin cancer, changes and becomes resistant to treatments, focusing on a protein called TFEB that might help us find better ways to help patients who aren't responding to current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 18, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $614,911 |
| NIH project number | 1R01CA289624-01 |
| Project ID | NIH-10858175 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced melanoma who have not responded to current therapies or have experienced a relapse.
✕Less likely to help
Patients with early-stage melanoma or those who have not yet undergone treatment may not benefit from this research.
What this research studies
This research investigates advanced melanoma, a severe form of skin cancer, focusing on how melanoma cells adapt and become resistant to therapies. It explores the role of a specific protein, TFEB, which is crucial for cell differentiation and may influence how melanoma cells respond to treatment. By studying the molecular mechanisms behind these changes, the research aims to identify new strategies to improve treatment outcomes for patients who currently do not respond to existing therapies. Patients may have their tumor profiles analyzed to understand the relationship between TFEB activity and treatment resistance.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that improve survival rates for patients with advanced melanoma.
How similar studies have gone: Other research has shown promising results in understanding the mechanisms of treatment resistance in melanoma, making this approach both relevant and potentially impactful.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Liang, Chengyu — Wistar Institute
- Study coordinator: Liang, Chengyu
Related research
Other NIH-funded projects on the same topics.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
-
PLK4 as a potential drug target in melanoma
Researchers are exploring whether blocking PLK4 could be a new way to treat melanoma and how PLK4 works with other melanoma-driving pathways.
-
A new lentivector to deliver multiple TCRs for melanoma cell therapy
A new gene-delivery approach aims to boost T cell receptors inside patients’ own cells to treat advanced melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.